Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Interventional 8 Observational 1

Sponsor

Conditions

Diabetes Mellitus, Type 2 1

Interventions

Surveys and Questionnaires 543 Blood Specimen Collection 447 Surgical Procedures, Operative 165 Observation 152 Drug Therapy 143 Radiotherapy 142 Interviews as Topic 139 Gene Expression Profiling 129 Biopsy 117 Magnetic Resonance Spectroscopy 116 Immunohistochemistry 112 Data Collection 95 Polymerase Chain Reaction 87 Specimen Handling 81 Amplified Fragment Length Polymorphism Analysis 81 Bevacizumab 79 Microarray Analysis 76 Flow Cytometry 69 Neoadjuvant Therapy 68 Watchful Waiting 67 Magnetic Resonance Imaging 65 Immune Checkpoint Inhibitors 62 Nivolumab 60 Immunotherapy 57 Therapeutics 55 Reverse Transcriptase Polymerase Chain Reaction 52 pembrolizumab 50 Ultrasonography 47 Positron Emission Tomography Computed Tomography 47 Hematologic Tests 47

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × empagliflozin × Clear all

NCT03464045 2025-04-20

Empa PASS on Urinary Tract Malignancies

Boehringer Ingelheim

344,995 enrolled 12 charts

Diabetes Mellitus, Type 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡